Email: cspc@cspc.cn
News
News Center
Jun. 18
2026
VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION
Jun. 16
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS)
Jun. 10
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR FIRST-LINE TRE
Jun. 08
SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
